Aeras Announces New CEO and Leadership Structure
Jacqueline Shea will assume CEO role in August
Rockville, MD., July 15, 2015 – Aeras announced today a new leadership structure for the nonprofit biotech organization with Jacqueline E. Shea, Ph.D., the current Chief Operating Officer (COO), assuming the role of Chief Executive Officer (CEO), effective August 12. Thomas G. Evans, M.D., will step down as CEO to become Acting Chief Scientific Officer (CSO). Ann M. Ginsberg, M.D., Ph.D., will continue as Chief Medical Officer.
Dr. Evans will serve as Acting CSO while Aeras considers how it wishes to fill the position permanently. “I am extremely happy that Dr. Shea will be leading Aeras as we continue our important work of tuberculosis (TB) vaccine development,” said Dr. Evans. “She is an outstanding choice and I am tremendously pleased to know that Aeras leadership will be in her capable hands. This is the right time for me and the organization to make this change, after five years with Aeras first as CSO, then CEO. As Acting CSO, I will be able to focus on the work I most enjoy. There is much unfinished work for me to do in the science arena, and I am looking forward to having the time to concentrate on a number of exciting TB projects.”
Dr. Shea joined Aeras as COO in April 2014, with more than 20 years of experience in the life sciences. “I came to Aeras last year to be part of the global effort to develop critically needed TB vaccines,” said Dr. Shea. “I’ve enjoyed working with Tom and the entire Aeras team and am looking forward to the challenge of this enhanced leadership role, expanding on Tom’s great work.”…